Banque Cantonale de Geneve (0RMP)
London Exchange · UK · prices in GBP · close of 20 Oct 2026
Key indicators
| Last close | GBP 33.90 |
|---|---|
| 52-week range | 23.70 – 36.99 |
| Return, 1 month / 3 months | +2.4% / +3.7% |
| Return, 1 year / 3 years | +40.1% / – |
| Trend | Uptrend |
| RSI (14) | 54 |
| Volatility (1 year) | 20.1% |
| Worst drawdown (1 year) | -18.2% |
| Average daily value traded | 0.12M GBP |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Banque Cantonale de Genève is a Swiss cantonal bank based in Geneva. It serves private individuals, small and medium-sized businesses and public bodies, mainly in the Geneva region. Its services include savings and deposit accounts, mortgages and other lending, payment services, and wealth and investment management for personal and corporate clients. The bank also supports local companies with business banking and financing, and works with institutional and public-sector customers.
On this site Banque Cantonale de Geneve appears as a stock on the London Exchange (UK), code 0RMP, with prices in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Banque Cantonale de Geneve (0RMP) trades on the London Exchange in UK. It last closed at GBP 33.90 on 20 October 2026.
Its price-based Market X-Ray is 59 out of 100 (a fair price profile), ranking 1,394 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 40.1% and over the last three months it rose 3.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 65 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 5.8% | ||
| From 52-week high | -8.3% | ||
| Momentum | 62 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.7% | ||
| 6-month return | -4.2% | ||
| 12-month return, skipping the last month | 36.8% | ||
| Stability (higher is calmer) | 82 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 20.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.2% | ||
| Liquidity | 32 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.12M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | 23 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.6% |
|---|---|
| 1 month | +2.4% |
| 3 months | +3.7% |
| 6 months | −4.2% |
| 1 year | +40.1% |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 32.76 / 32.03 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.44 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | GBX 0.0053 |
| 6 May 2025 | GBX 0.0160 |
| 30 Apr 2024 | GBX 0.0160 |
| 4 May 2023 | GBX 0.0135 |
| 11 May 2022 | GBX 0.0110 |
| 5 May 2021 | GBX 0.0280 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.